What is the dosing frequency for Firmagon?

The dosing frequency for Firmagon, also known as degarelix, is every 28 days. This medication is indicated for the treatment of advanced prostate cancer and is administered as a subcutaneous injection. The 28-day dosing schedule is designed to maintain adequate hormone suppression, specifically the suppression of testosterone, which is a key factor in the growth of prostate cancer cells.

Firmagon works by blocking the action of gonadotropin-releasing hormone (GnRH), leading to a rapid reduction in testosterone levels. This therapeutic approach necessitates a consistent dosing interval to ensure that the hormone levels remain effectively controlled. Adherence to this 28-day schedule is crucial for maximizing the treatment benefits while minimizing potential side effects associated with fluctuating hormone levels.

Other intervals such as every 7, 14, or 21 days do not align with the pharmacokinetic properties of Firmagon and would not provide the intended therapeutic benefits, impacting the control of prostate cancer progression.